Trump Criticizes ABC, NBC and CNN for Limiting Coverage of Election Speech 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Seven & i Eyes Żabka Stake in Major European Expansion Push 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
DeepSeek Eyes $74 Billion Valuation Ahead of Planned China IPO 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
British pharmaceutical giant GSK plc (LON:GSK) is reportedly in advanced negotiations to acquire U.S.-based cancer drug developer Nuvalent Inc. (NASDAQ: NUVL) in a deal that could be worth more than $9 billion, according to a report published by the Financial Times on Tuesday.
Sources familiar with the matter said both companies are working toward finalizing an agreement as early as this week. However, discussions remain ongoing, and there is still a possibility that the deal could fall through if last-minute challenges arise.
If completed, the proposed acquisition would value Massachusetts-headquartered Nuvalent between $9 billion and $10 billion. The valuation represents a substantial premium over Nuvalent’s market capitalization, which stood at nearly $7 billion at the close of trading on Monday.
The potential takeover would mark GSK’s largest acquisition in more than a decade and rank among the most significant transactions in the company’s history. The move aligns with CEO Luke Miels’ strategy to expand and strengthen GSK’s oncology portfolio as the pharmaceutical industry increasingly focuses on innovative cancer treatments.
Nuvalent has gained attention for its work in developing targeted cancer therapies designed to address resistance mechanisms in tumors. Its lead drug candidate, neladalkib, is being developed for the treatment of lung cancer and is currently under review by U.S. regulators. Approval of the therapy could significantly enhance Nuvalent’s value and commercial prospects.
The reported deal comes during a period of heightened activity in the global biotechnology sector. According to Dealogic data cited in the report, biotech and pharmaceutical mergers and acquisitions have reached nearly $211 billion in announced transactions so far this year, highlighting strong demand for promising drug-development companies.
Should the acquisition move forward, it would further reinforce GSK’s commitment to cancer research and provide the company with valuable assets in the rapidly growing oncology market.
